Revlimid Rivals Debut In Canada
Lenalidomide Launches By Dr Reddy’s And Natco Follow Settlements With Celgene
Dr Reddy’s and Natco have announced launches of Canadian rivals to Celgene’s Revlimid, with lenalidomide capsules from both companies made available from the start of September following settlements with the originator.
You may also be interested in...
Biogen Launches Lucentis Biosimilar Byooviz In Canada
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
Dr Reddy’s Must Notify Celgene Of Plans To Sell Revlimid Generic In Australia
Australia’s Federal Court has ordered Dr Reddy’s to provide Celgene with three months written notice that it intends to bring a generic lenalidomide Revlimid rival to market.
Dr Reddy’s Eyes Generic Revlimid Exclusivity With ANDA Approval
With Natco poised to debut the first batch of Revlimid generics in the US in March next year, fellow Indian ANDA sponsor Dr Reddy’s Laboratories has secured its own approval from the FDA for two strengths of the blockbuster multiple myeloma treatment.